10/28/2019 | DD | Market Commentary: PG&E dives as blackouts, wildfires persist; McDermott declines after ratings downgrade
|
10/9/2019 | DD | Market Commentary: U.S. Steel notes weaken after CFO departure; PG&E lower amid exclusivity termination
|
10/1/2019 | DD | Market Commentary: U.S. Steel notes lower on acquisition news; Mallinckrodt active in pharmaceutical space
|
9/13/2019 | DD | Market Commentary: PG&E bonds lower on insurance settlement news; Mallinckrodt better in pharma space
|
9/6/2019 | DD | Market Commentary: Mallinckrodt mixed on settlement news; PG&E better in run-up to restructuring plan
|
9/5/2019 | DD | Market Commentary: Mallinckrodt sinks on restructuring talk; Bed Bath better after announcing revamp plan
|
8/27/2019 | DD | Market Commentary: Endo, Teva drop post-settlement news; Range Resources active, flat after downgrade
|
8/26/2019 | DD | Market Commentary: Endo, Mallinckrodt notes better on settlement news; DISH rises after analyst upgrade
|
8/23/2019 | DD | Market Commentary: L Brands bonds lower after analyst downgrade; Endo paper declines in pharma space
|
8/22/2019 | DD | Market Commentary: L Brands bonds active, mixed after earnings report; CBL eyed after delisting notice
|
8/21/2019 | DD | Market Commentary: L Brands lower on earnings anticipation; Endo International notes continue to rise
|
8/20/2019 | DD | Market Commentary: Endo International gains after lawsuit settlement news; PG&E weakens in utilities space
|
3/26/2019 | BKCVDDEMIGPV | Market Commentary: Allison Transmission oversubscribed; Endo, Par Pharma jump; Bed Bath & Beyond surges
|
3/15/2019 | BKCVDDEMIGPV | Market Commentary: Power Solutions carries over; SS&C Technologies, Par in focus; Community Health drops
|
3/14/2019 | BKCVDDEMIGPV | Market Commentary: SS&C Technologies, Endo price; Amkor, Ashton Woods trade up; funds add $1.04 billion
|
3/14/2019 | DD | Market Commentary: Endo notes positive as company begins debt refinancing; PHI issues dip over maturity fears
|
3/14/2019 | BKDDHY | Moody’s cuts Endo debt, rates revolver, notes Ba3
|
3/14/2019 | BKDDHY | S&P trims Endo International, rates Par Pharma notes B+
|
2/10/2015 | BKDDHY | Moody's changes Par to stable, rates add-on B1
|
2/3/2014 | BKDDHY | S&P cuts Par Pharmaceutical
|
6/25/2009 | CVDD | Par Pharmaceutical avoids acceleration of 2.875% convertibles
|
10/6/2006 | BTCVDD | Par Pharmaceutical receives acceleration notice on $200 million 2.875% convertibles
|
9/6/2006 | BTCVDD | Par Pharmaceutical receives disputed default notice on 2.875% convertibles
|